Revenues for the quarter were ₹122 Cr (43.5% growth YoY). Gross profit margins have increased from 61% in Q3 FY21 to 66% in Q3 FY22. EBITDA stood at ₹43 Cr(43% growth YoY) and EBITDA margins increased from 35% in Q3 FY21 to 36% inQ3 FY22. The EBITDA margins have dipped slightly YoY for the 9 …
Supriya Life Scieneces Q3 2022 Concall Highlights Read More »
Revenues for the quarter were ₹9814 Cr (11% growth YoY). Material cost as a percentage of revenues was 27%. Staff cost was up by 8% YoY and stands at 18.9% of revenues. Other expenses were up 13% YoY and stands at 28.1% of revenues. The increase is attributed towards higher selling & distribution and traveling …
Revenues for the quarter stood at ₹796 Cr (5% decline YoY). Gross margins decline by 840 bps YoY. Gross margin compression is due to product mix and they had inventory of increased RM prices which were adjusted to the lower realizations they received. They are seeing an uptick in opportunities in the regulated markets and …
During the quarter, Revenues stood at ₹81 Cr (12% growth YoY), EBITDA was at ₹12.5 Cr (44% decline YoY) and PAT stood at ₹9.9 Cr (44% decline YoY). Gross margins were at 48% (compared to 60% in Q3 FY21) and EBITDA margins were 15.4% (30.8% in Q3 FY21). Continuing rise in input prices (27% YoY …
Revenue for the quarter is ₹238.4 Cr (2.9% decline YoY). EBITDA for the quarter was ₹34.2 Cr (26.8% decline YoY) with an EBITDA margin of 14.3%. They are facing supply chain issues due to raw material volatility and high logistics cost. They also benefited in the last few quarters due to raw material hedging for …
The company’s performance for the quarter was affected by headwinds in the pharmaceutical business. But was partly mitigated due to robust performance in the Contract Research and Development Services (CRDS) segment. While the Radiopharma business showed improved performance, Generics business was affected by lower volumes due to Import Alert at Roorkee plant, latest sartan impurities …
They were the fastest growing company among the Top 30 companies in the domestic formulations market as per IQVIA. JB grew at 27% vs market growth of 18%. Revenues for the quarter stood at ₹601 Cr (10% growth YoY). EBITDA excluding ESOP cost stood at ₹153 Cr (10.5% decline YoY). Gross margins for the quarter …
JB Chemicals & Pharma Q3 2022 Concall Highlights Read More »
Revenue for the quarter stood at ₹996.8 Cr (18% growth YoY). EBITDA for the quarter was at ₹173 Cr (17.9% decline YoY). EBITDA margins were at 17.4% compared to 25.1% in Q3 FY21. They faced challenges during the quarter such as RM price increases, unstable supply from China and logistics issues.Their volumes were down compared …
Revenue – ₹1063 Cr (24% growth YoY). EBITDA – ₹394 Cr (32% growth YoY). EBITDA margin stood at 36% PAT – ₹273 Cr (34% growth YoY) Almost 17-18% growth has come from increase in volumes and new launches have given 6% growth. So major growth has come volumes and new launches so price changes do …
Revenues for the quarter stood at ₹332 Cr (7% growth YoY). EBITDA for the quarter was at ₹122 Cr (13.5% growth YoY). EBITDA margin for the quarter was at 37%. PAT for the quarter was ₹101 Cr (12% growth YoY) The Guwahati facility contributed to 80% of the revenues for the quarter. Operating cash flow …